靶向PARP-1调控肿瘤细胞放射敏感性的研究进展  

Research progress of targeting PARP-1 to regulate radiosensitivity of tumor cells

作　　者：余晓军 左代英[2] 侯文彬 李祎亮[1] Yu Xiaojun;Zuo Daiying;Hou Wenbin;Li Yiliang(Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine,Institute of Radiation Medicine,Chinese Academy of Medical Sciences,Peking Union Medical College,Tianjin 300192,China;Shenyang Pharmaceutical University,Shenyang 121000,China)

机构地区：[1]中国医学科学院北京协和医学院放射医学研究所,天津市放射医学与分子核医学重点实验室300192 [2]沈阳药科大学,121000

出　　处：《国际放射医学核医学杂志》2021年第1期61-66,共6页International Journal of Radiation Medicine and Nuclear Medicine

基　　金：天津市自然科学基金(18JCQNJC09500);天津市科技计划项目(18ZXXYSY00110);中国医学科学院医学与健康科技创新工程项目(2016-I2M-3-022、2017-I2M-3-019);中央高校基本科研业务费专项资金(3332018117)。

摘　　要：放疗是晚期肿瘤的主要治疗手段,然而,由于肿瘤耐受和抵抗的出现,其治疗效果不佳。因此,纠正肿瘤放疗抵抗或提高其放疗敏感性成为迫切需要解决的问题。聚腺苷二磷酸核糖聚合酶(PARP)1是一种功能丰富的核蛋白,鉴于其在染色质结构调节和DNA损伤修复等细胞过程中的重要作用,PARP-1被认为是最具有潜力的一种放射增敏靶点。笔者就靶向PARP-1调控肿瘤细胞放射敏感性的研究进展作一综述。Radiotherapy is the main treatment for advanced tumor.However,due to the emergence of tumor tolerance and resistance,the treatment effect is not ideal.Therefore,it is urgent to correct the resistance or improve the sensitivity of radiotherapy.Poly(adenosine diphosphate-ribose)polymerase(PARP)1 is a member of a functionally rich nuclear protein.In view of its important role in cellular processes such as regulation of chromatin structure and repair of DNA damage,PARP-1 is considered to be the most potential target for radiosensitization.In this paper,the author reviews the research progress of targeting PARP-1 to regulate radiosensitization of tumor cells.

关 键 词：辐射增敏药 聚ADP核糖聚合酶类 肿瘤 

分 类 号：R730.55[医药卫生—肿瘤]